Date: 2017-04-05
Type of information: Nomination
Compound: chairman of the board of directors, chief medical officer
Company: Allecra Therapeutics (Germany - France)
Therapeutic area: Infectious diseases
Type agreement: nomination
Action mechanism:
Disease:
Details: • On April 5, 2017, Allecra Therapeutics announced two key appointments to strengthen its leadership team as the company enters its next phase of development. Dr. Engelbert Tjeenk Willink is appointed to the position of Chairman of the Board and Dr. Leon Hooftman is appointed to the position of Chief Medical Officer. Dr. Holger Reithinger of Forbion Partners steps down as Chairman and remains on Allecra’s Advisory Board. Dr. Tjeenk Willink brings more than 25 years’ experience within the pharmaceutical industry, most recently at Boehringer Ingelheim as a member of the Board of Managing Directors. He holds a number of non-executive board positions at smaller pharmaceutical and biotechnology companies. Dr. Leon Hooftman, Allecra’s new CMO, brings over 20 years’ successful experience in biopharmaceutical drug development. Previous positions include Head of Clinical Development at Celltech Group plc and Chief Medical Officer of Chroma Therapeutics. Dr. Hooftman joins Allecra from his role as CMO of Polyphor , a Swiss biopharmaceutical company. Allecra is focused on the development of novel treatments to combat multi drug-resistant Gram-negative bacterial infections.
Financial terms:
Latest news:
